Effect of local injection of botulinum toxin versus nasal fluticasone spray on clinical sign and symptoms in patients with allergic rhinitis

Effect of local injection of botulinum toxin versus nasal fluticasone spray on clinical sign and symptoms in patients with allergic rhinitis: a triple blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201506079014N67

Enrollment

Registered

2015-06-16

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis. Allergic rhinitis, unspecified

Interventions

Intervention 1: Single dose injection of 50 unit Dysport dissolved in 0.1 ml normal saline in the frontal head of the inferior nasal turbinate in either side plus normal saline spray two puffs every 1

Treatment - Drugs

Placebo

Single dose injection of 50 unit Dysport dissolved in 0.1 ml normal saline in the frontal head of the inferior nasal turbinate in either side plus normal saline spray two puffs every 12 hours in eithe

Single dose injection of 0.1 ml normal saline in the frontal head of the inferior nasal turbinate in either side plus normal saline spray two puffs every 12 hours in either side of the nose for 8 week

Eligibility

Sex/Gender

All

Age

8 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (a) age of 18 to 70 years; (b) having allergic rhinitis. Exclusion criteria: (a) pregnancy or breastfeeding; (b) contraindication of corticosteroids; (c) having severe anatomical abnormality in nose or acute rinosinusitis; (d) having glaucoma or prostatic hypertrophy; (e) having severe systemic diseases such as diabetes or asthma; (f) simultaneous using aminoglycoside drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Assessing nasal congestion. Timepoint: 8 weeks after intervention. Method of measurement: through physical examination.;Assessing rhinorrhea. Timepoint: 8 weeks after intervention. Method of measurement: through taking history.;Assessing nasal itching. Timepoint: 8 weeks after intervention. Method of measurement: through taking history.;Assessing sneezing. Timepoint: 8 weeks after intervention. Method of measurement: through taking history.	—

Measure

Time frame

Assessing nasal congestion. Timepoint: 8 weeks after intervention. Method of measurement: through physical examination.;Assessing rhinorrhea. Timepoint: 8 weeks after intervention. Method of measurement: through taking history.;Assessing nasal itching. Timepoint: 8 weeks after intervention. Method of measurement: through taking history.;Assessing sneezing. Timepoint: 8 weeks after intervention. Method of measurement: through taking history.

—

Secondary

Measure	Time frame
Assessing dizziness. Timepoint: 8 weeks after intervention. Method of measurement: through taking history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Somayeh damadi

Besat Hospital

somayedamadi@yahoo.com+98 81 3364 0030

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026